i-Lumen Scientific Announces First U.S. Patient Randomized in i-SIGHT2 Pivotal Study Evaluating Noninvasive Bioelectric Therapy for Intermediate to Advanced Dry AMD

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

i-LUMEN-iSIGHT2-Study

More Like This

PR Newswire associated0

i-Lumen Scientific Receives FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD

LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)

LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026

MacuMira and Keeler announce strategic partnership to expand Dry AMD therapy